# ADC Therapeutics S.A. clinical trials: 21 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with ADC Therapeutics S.A. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by ADC Therapeutics S.A.: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/adc-therapeutics-s-a

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 21, 2022 | NCT05660395 | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large... | ADC Therapeutics S.A. | Phase 1 | Terminated | Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05660395) |
| May 25, 2022 | NCT05389462 | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | ADC Therapeutics S.A. | Phase 1 | Terminated | Advanced Solid Tumors | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05389462) |
| December 16, 2021 | NCT05160064 | Long-term Registry of Patients Treated With Loncastuximab Tesirine | ADC Therapeutics S.A. | Observational | Withdrawn | B-Cell Lymphomas | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05160064) |
| December 3, 2021 | NCT05144009 | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell... | ADC Therapeutics S.A. | Phase 2 | Terminated | Diffuse Large B-cell Lymphoma | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05144009) |
| July 23, 2021 | NCT04974996 | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With... | ADC Therapeutics S.A. | Phase 1 | Withdrawn | Diffuse Large B-Cell Lymphoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04974996) |
| July 22, 2021 | NCT04972981 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced... | ADC Therapeutics S.A. | Phase 1 | Completed | Advanced Solid Tumors | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04972981) |
| July 21, 2021 | NCT04970901 | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in... | ADC Therapeutics S.A. | Phase 1 | Active not recruiting | B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04970901) |
| January 12, 2021 | NCT04705454 | Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | ADC Therapeutics S.A. | Not applicable | No longer available | Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04705454) |
| January 7, 2021 | NCT04699461 | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory... | ADC Therapeutics S.A. | Phase 2 | Terminated | Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04699461) |
| May 12, 2020 | NCT04384484 | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large... | ADC Therapeutics S.A. | Phase 3 | Active not recruiting | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04384484) |
| August 12, 2019 | NCT04052997 | Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma | ADC Therapeutics S.A. | Phase 2 | Completed | Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | 117 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04052997) |
| October 9, 2018 | NCT03700294 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | ADC Therapeutics S.A. | Phase 1 | Terminated | Advanced Solid Tumors | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03700294) |
| September 26, 2018 | NCT03685344 | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma | ADC Therapeutics S.A. | Phase 1 | Terminated | Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03685344) |
| September 26, 2018 | NCT03684694 | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma | ADC Therapeutics S.A. | Phase 1/2 | Terminated | Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03684694) |
| August 9, 2018 | NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | ADC Therapeutics S.A. | Phase 1 | Terminated | Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer, Pancreas... | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03621982) |
| July 18, 2018 | NCT03589469 | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | ADC Therapeutics S.A. | Phase 2 | Completed | Diffuse Large B-Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | 145 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03589469) |
| April 24, 2017 | NCT03125200 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression | ADC Therapeutics S.A. | Phase 1 | Terminated | Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer, Bladder Cancer | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03125200) |
| February 1, 2016 | NCT02669264 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) | ADC Therapeutics S.A. | Phase 1 | Terminated | Acute Lymphoblastic Leukemia | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02669264) |
| January 29, 2016 | NCT02669017 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | ADC Therapeutics S.A. | Phase 1 | Completed | Non-Hodgkin Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma... | 183 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02669017) |
| October 27, 2015 | NCT02588092 | Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic... | ADC Therapeutics S.A. | Phase 1 | Terminated | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02588092) |
| May 4, 2015 | NCT02432235 | Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma | ADC Therapeutics S.A. | Phase 1 | Completed | Hodgkin Lymphoma, Non-Hodgkin Lymphoma | 133 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02432235) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 13 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 3 | 1 |
| Not applicable | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Terminated | 11 |
| Completed | 5 |
| Active not recruiting | 2 |
| Withdrawn | 2 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Lymphoma, Large B-Cell, Diffuse | 9 |
| Lymphoma | 7 |
| Lymphoma, Non-Hodgkin | 4 |
| Lymphoma, Follicular | 3 |
| Lymphoma, Mantle-Cell | 3 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Urinary Bladder Neoplasms | 2 |
| Lymphoma, B-Cell | 2 |
| Hodgkin Disease | 2 |
| Recurrence | 2 |
| Pancreatic Neoplasms | 2 |
| Leukemia, Myeloid, Acute | 1 |
| Breast Neoplasms | 1 |
| Burkitt Lymphoma | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Waldenstrom Macroglobulinemia | 1 |
| Stomach Neoplasms | 1 |
| Esophageal Neoplasms | 1 |
| Carcinoma, Renal Cell | 1 |
| Melanoma | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Ovarian Neoplasms | 1 |
| Colonic Neoplasms | 1 |
| Fallopian Tube Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Acupuncture clinics in the United States](https://specstream.ai/data/businesses/acupuncture-clinics/united-states)
- [Tea wholesalers in the United States](https://specstream.ai/data/businesses/tea-wholesalers/united-states)
- [Rail freight companies in the United States](https://specstream.ai/data/businesses/rail-freight-companies/united-states)
- [Oral and maxillofacial surgery practices in the United States](https://specstream.ai/data/businesses/oral-and-maxillofacial-surgery-practices/united-states)
- [Kosher restaurants in the United States](https://specstream.ai/data/businesses/kosher-restaurants/united-states)
- [Glass companies in the United States](https://specstream.ai/data/businesses/glass-companies/united-states)
